Latest News
Frost & Sullivan Sees Microdosing as Compelling Advantage for Big Pharma
Date Posted: |
10 Feb 2009 |
Summary: |
LONDON - 10 February, 2009 - Microdosing or Phase 0 clinical testing has been gaining acceptance and might become an imperative phase of the drug development process in the years to come. The emergence of niche capability providers in preclinical testing and technology dependence is also expected to result in numerous partnerships and alliances, fuelling growth opportunities in this sector.
|
|
"There is every reason to believe that the solution for faster screening of candidates and increasing pressure on costs is gaining momentum in the right direction," notes Frost & Sullivan (http://www.pharma.frost.com) Senior Research Analyst V. Sriram. "The compelling advantages of microdosing present it as a potential remedy for big pharma's maladies regarding declining returns from investments in drug development."
To read more, go to: www.frost.com/prod/servlet/press-release.pag?docid=158498629&ctxst=FcmCtx1&ctxht=FcmCtx2&ctxhl=FcmCtx3&ctxixpLink=FcmCtx3&ctxixpLabel=FcmCtx4
Click to see more news
